← Back to All Filings

Precision Bio Insider Sells $22K in Stock for Tax Obligations

Low SignificanceNovember 3, 2025 at 3:32:17 PM EST

PRECISION BIOSCIENCES INC

$DTIL144CIK: 0001357874

Subscribe to track DTIL

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Precision Bio Insider Sells $22K in Stock for Tax Obligations

Company: PRECISION BIOSCIENCES INC (DTIL) Form: 144 | Filed: 2025-11-03 Significance: Low

Insider: Amoroso Michael Title: Officer | Relationship: Officer, Director

Transaction: • Type: Sale (Proposed) • Shares: 3,409 • Price: ~$6.49 • Value: $22,121 • Owned After: Not Stated

Key Insight: This is a minor, non-discretionary sale to cover tax liabilities from vested stock awards, not an indicator of negative insider sentiment.

Market Context: The transaction represents a negligible 0.022% of the company's $100M market cap.

View Full Filing

This is PUBLIC SEC data for educational purposes. Not investment advice.

Comprehensive Analysis

SEC Filing Analysis: PRECISION BIOSCIENCES INC (DTIL)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: An officer and director filed a notice of a proposed sale of shares valued at approximately $22,121, explicitly to cover tax obligations from vested equity awards.
  • Market Impact: The transaction is immaterial and non-discretionary, suggesting a neutral market impact.

Company Information

FieldValue
CompanyPRECISION BIOSCIENCES INC
Ticker SymbolDTIL
CIK0001357874
IndustryBIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

FieldValue
NameAmoroso Michael
CIK0001830874
Title/PositionOfficer
RelationshipOfficer, Director

Transaction Details

FieldValue
Form Type144 (Notice of Proposed Sale)
Transaction Date2025-11-03 (Approx. Sale Date)
Transaction CodeS (Sale)
Security TypeCommon
Shares Involved3,409
Price Per Share~$6.49 (Calculated)
Total Value$22,121
Shares Owned AfterNot Stated
Ownership TypeNot Stated

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$22,121
% of Market Cap0.022%
Shares Transacted3,409
% of Shares Outstanding0.029%
Post-Transaction OwnershipNot Stated
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: For a company with a market capitalization of $100 million, this $22,121 transaction is negligible.
  • Ownership Concentration: Without post-transaction ownership data, a full assessment is not possible, but the size of the sale is too small to materially affect ownership levels.
  • Transaction Significance: The sale represents less than 0.03% of both the market cap and shares outstanding, falling well below any threshold for significance. The stated purpose as a "sell-to-cover" for tax obligations confirms its low importance as a market signal.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The transaction is a routine, non-discretionary sale to cover taxes. It is extremely small relative to the company's market capitalization and does not reflect a change in the insider's outlook on the company.

Volume & Sentiment

  • Expected Volume Impact: Negligible. The number of shares is too small to impact daily trading volume.
  • Sentiment Indicator: Neutral. This type of filing is common and does not carry bullish or bearish sentiment.

Additional Context

Transaction Notes

  • Special Circumstances: The filing explicitly states, "Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution." This is a classic "sell-to-cover" transaction, which is automated and not based on the insider's discretion or market timing.
Topics:#SECFiling#InsiderTrading#DTIL#PrecisionBiosciences#Form144#InsiderSell#StockMarket#Biotech#Finance

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.